The Oregon Cancer Center was created in 1991 as a multidepartmental institute of Oregon Health Sciences University in Portland. The goals of the center are to support both basic and clinical cancer research activities on this campus and to facilitate application of the latest research opportunities to the diagnosis, treatment, and prevention of malignant diseases. The Center received support through a Cancer Center Planning Grant (P20) in 1992. The Center has four scientific programs (Caner Biology, Hormonal and Reproductive Cancers, Hematologic Malignancies, and Experimental Therapeutics) and one developing program (Cancer Prevention and Control) with effect our shared views that: (a) the best new strategies for diagnosis, treatment, and control depend upon the identification of specific pathophysiological significant molecular defects in neoplastic cells and (b) a comprehensive definition of normal cellular growth and differentiation is required to define specific molecular defects in neoplastic cells. In support of the activities of the center are seven shared resources (Flow Cytometry, Molecular Biology, Tumor Procurement, Cell Culture and Expression, Animal Models, Biostatistics, and Clinical Research Management). The commitment of more than $27 million to our development has resulted, to date, in the recruitment of 29 new members to the facilities of various Departments in the University, creation of seven shared facilities, and design, construction, or renovation of new space. The Cancer Center Director controls 21,825 square feet of centrally located space of campus (11,000 square feet of which represents the top floor of a new building that will serve as our Headquarters in July 1997, the move-in date). In November 1998 our space will more than double by virtue of the completion of a $32.2 million Cancer Research building on the VA campus, half of which will be assigned to the Center. The Center has established a new set of operating principles that have resulted in the creation of a variety of innovative institutional clinical trials on this campus. Consequently, the Oregon Cancer Center has gained widespread acceptance by both basic and clinical cancer research faculty on this campus and has been welcomed by cancer caregivers throughout Oregon and Southwestern Washington.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA069533-03S1
Application #
2858502
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Ciolino, Henry P
Project Start
1997-08-01
Project End
2000-05-31
Budget Start
1999-07-12
Budget End
2000-05-31
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6

Showing the most recent 10 out of 277 publications